Evidence map›Paper›PMID 39239277›Full record

ArticleFrontiers in oncology2024

The European Larynx Organ Preservation Study [MK-3475-C44].

Gunnar Wichmann, Theresa Wald, Markus Pirlich, Joanna Napp, Ina Münter, Thomas Asendorf, Ralf Tostmann, Jeannette Vogt, Kathrin Vogel, Sylvia Meuret and 9 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06137378 (ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response Evaluation), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06137378 phase2recruitingnot on this map

ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response Evaluation

TypeinterventionalSponsorUniversity of LeipzigRan2024 to 2030Enrolled140ConditionsSquamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IVArmsKEYTRUDA®
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. "Histologic type, treatment and prognosis of carcinomas of the larynx: A review".Virchows Archiv : an international journal of pathology · 2026
    Review
  3. Article
  4. Review
  5. Systemic therapy for laryngeal carcinoma.Frontiers in oncology · 2025
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gunnar Wichmann *Clinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.
Theresa Wald *Clinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.
Markus PirlichClinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.
Joanna NappClinical Trial Unit, University Medical Center Goettingen, Göttingen, Germany.
Ina MünterDepartment of Medical Statistics, University Medical Center Goettingen, Goettingen, Germany.
Thomas AsendorfDepartment of Medical Statistics, University Medical Center Goettingen, Goettingen, Germany.
Ralf TostmannClinical Trial Unit, University Medical Center Goettingen, Göttingen, Germany.
Jeannette VogtClinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.
Kathrin VogelClinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.
Sylvia MeuretClinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.
Matthaeus StoehrClinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.
Veit ZebrallaClinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.
Nils Henrik NicolayThe Comprehensive Cancer Center Central Germany, Leipzig University Hospital, Leipzig, Germany.
Thomas KuhntThe Comprehensive Cancer Center Central Germany, Leipzig University Hospital, Leipzig, Germany.
Peter HambschThe Comprehensive Cancer Center Central Germany, Leipzig University Hospital, Leipzig, Germany.
Orlando Guntinas-LichiusENT Department, Jena University Hospital, Jena, Germany.
Jens Peter KlußmannDepartment of Oto-Rhino-Laryngology Head and Neck Surgery, University of Cologne, Cologne, Germany.
Susanne Wiegand *Clinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.
Andreas Dietz *Clinic for Otorhinolaryngology and Head and Neck Surgery, Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Larynx Organ Preservation Study (ELOS; NCT06137378) is a prospective, randomized, open-label, two-armed parallel group controlled, phase II multicenter larynx organ preservation (LOP) trial in locoregionally advanced (LA) stage III, IVA/B head and neck squamous cell carcinoma of the larynx or hypopharynx (LHSCC) amenable for total laryngectomy (TL) with PD-L1 expression within tumor tissue biopsy, calculated as CPS ≥ 1. Induction chemotherapy (IC) with docetaxel and cisplatin (TP) followed by radiation will be compared to TP plus PD-1 inhibition by pembrolizumab (MK-3475; 200 mg i.v. starting day 1 q3w for 17 cycles). After a short induction early response evaluation (ERE) 21 ± 3 days after the first cycle of IC (IC-1), responders achieving endoscopic estimated tumor surface shrinkage (ETSS) ≥30% will get an additional two cycles of IC followed by intensity-modulated radiotherapy 70-72 Gy (EQD2/α/β = 10) aiming at LOP. Nonresponders (ETSS < 30% or progressing disease) will receive TL and bilateral neck dissection followed by postoperative radiation or chemoradiation as recommended by the clinic's multidisciplinary tumor board. Pembrolizumab treatment will be continued in the intervention arm regardless of ETSS status after IC-1 in both responders and laryngectomized nonresponders, independent of subsequent decisions on adjuvant therapy after TL. Clinical Trial Registration: clinicaltrials.gov, identifier NCT06137378.

Indexed as

head and neck squamous cell carcinoma (HNSCC)immune checkpoint blockade PD-1:PD-L1 axisinductionchemotherapy (IC)larynx and hypopharynx cancer (LHSCC)larynx organ functionlarynx organ preservation (LOP)randomized controlled trial (RCT)total laryngectomy (TL)

Identifiers

PMID39239277
PMCPMC11374655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.